Evidence map›Paper›PMID 39394958›Full record

ArticleEuropean journal of haematology2025

Biological Findings and Clinical Outcomes in Patients Treated With R-CHOP Plus High-Dose Methotrexate as First-Line Therapy in Large B-Cell Lymphoma With Testis Involvement.

R Liévin, B Burroni, E Balducci, P Palmic, J Decroocq, B Deau-Fischer, P Franchi, M Vignon, J Zerbit, A S Cottereau and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

R LiévinClinical Hematology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.ORCID https://orcid.org/0000-0002-5097-591X
B BurroniPathology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
E BalducciCytogenetics Department, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris, Paris, France.
P PalmicPathology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
J DecroocqClinical Hematology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
B Deau-FischerClinical Hematology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
P FranchiClinical Hematology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
M VignonClinical Hematology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
J ZerbitPharmacy Department, AP-HP, Hospitalisation à Domicile APHP, Université de Paris, Paris, France.
A S CottereauNuclear Medicine Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
A TouzartLaboratory of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.
P VillareseCytogenetics Department, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris, Paris, France.
S KaltenbachCytogenetics Department, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris, Paris, France.
L LhermitteCytogenetics Department, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris, Paris, France.
V AsnafiCytogenetics Department, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris, Paris, France.
D BouscaryClinical Hematology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
L WillemsClinical Hematology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary testicular lymphoma (PTL) is a rare occurrence of diffuse large B-cell lymphoma (DLBCL) that accounts for 1%-2% of all cases. Nodal DLBCL with testis involvement (DLBCL-T) and PTL are associated with poor prognosis, with high incidence of central nervous system relapse. Fifteen patients (median age 60 years) with PTL (n = 5) or DLBCL-T (n = 10) received high-dose methotrexate + R-CHOP. Overall, complete response (CR) rate was 73% and overall response rate 86%. With a 3.9-year median follow-up, 100% of patients with PTL had CR and none relapsed. On the contrary, 55% of DLBCL-T patients achieved CR among which only one was still in remission at the end of follow-up. Molecular parallels between PTL and Primary CNS Lymphoma (PCNSL) suggest shared origins, urging further research for tailored treatments and enhanced understanding of these lymphomas' biology.

Indexed as

Antibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinLymphoma, Large B-Cell, DiffuseMethotrexatePrednisoneRituximabTesticular NeoplasmsVincristineAdultAgedHumansMaleMiddle AgedTreatment OutcomeAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinMethotrexatePrednisoneR-CHOP protocolRituximabVincristineCNS relapseDLBCLmethotrexatetestis

Identifiers

PMID39394958
PMCPMC11613630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.